Eli Lilly and Company (NYSE:LLY) Shares Purchased by Horan Capital Advisors LLC.

Horan Capital Advisors LLC. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.2% in the 4th quarter, HoldingsChannel reports. The fund owned 750 shares of the company’s stock after acquiring an additional 44 shares during the period. Horan Capital Advisors LLC.’s holdings in Eli Lilly and Company were worth $437,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Simon Quick Advisors LLC boosted its stake in Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $363,000. Terril Brothers Inc. increased its position in Eli Lilly and Company by 113.2% during the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after buying an additional 429 shares during the period. Hartline Investment Corp increased its position in Eli Lilly and Company by 1.1% during the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after buying an additional 248 shares during the period. Finally, Commonwealth Equity Services LLC lifted its stake in Eli Lilly and Company by 5.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company’s stock valued at $206,683,000 after buying an additional 17,461 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY traded down $20.94 during mid-day trading on Friday, reaching $734.97. 4,595,138 shares of the company’s stock were exchanged, compared to its average volume of 2,629,045. Eli Lilly and Company has a 52-week low of $419.80 and a 52-week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company has a 50-day simple moving average of $761.06 and a two-hundred day simple moving average of $671.38. The company has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a PEG ratio of 1.46 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.62 earnings per share. On average, sell-side analysts predict that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LLY. Bank of America lifted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. BMO Capital Markets upped their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.